The Speaker
Wednesday, 17 July 2024 – 19:56

Single dose COVID-19 vaccine 66% effective in phase three trials

Belgian pharmaceutical company Janssen has announced that their COVID-19 vaccine is 66% effective.

The UK has already got 30 million doses of the vaccine on pre-order, which can be transported at temperatures of 2-8°C.

Phase 3 trials of the vaccine had looked at giving just one dose of the vaccine to participants, though Janssen is also investigating whether giving two doses of their vaccine would improve the protection it offers. Currently, the COVID-19 vaccines being used in the UK both require two doses.

The company, which is owned by Johnson & Johnson, said that its initial findings showed that one dose prevented 85% of the most severe Coronavirus cases, however, the vaccine was just 57% effective in trials in South Africa where a new variant of the virus has been spreading.

Health Secretary Matt Hancock welcomed the news and thanked everyone involved in vaccination efforts.

The news comes shortly after it was announced that a vaccine developed by Novavax was 89.3% effective in preventing Coronavirus trial participants.

So far, more than 7.4 million people have received their first dose of a COVID-19 vaccine in the UK, with the government aiming to vaccinate 15 million of the most vulnerable people by 15 February.

Skip to content